Work

The pharmacological management of NAFLD in children and adolescents

Year: 2017
Type: review
Abstract: Savinda Liyanagederaa, Robert Patrick Williamsa, Silvio Veraldibc, Valerio Nobilibc & Jake P. Mann*de http://orcid.org/0000-0002-4711-9215a Department of Paediatrics, Cardiff University School of Medicine, Cardiff, UKb Hepatometabolic Unit, Bambino Gesu Hospital – IRCCS, Rome, Italyc Liver Research Unit, Bambino Gesu Hospital, IRCCS, Rome, Italyd Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Cambridge, UKe Department of Paediatrics, University of Cambridge, Cambridge, UKCONTACT Jake P. Mann [email protected] Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke’s Hospital, Hills Rd, Cambridge CB2 0QQ, UKABSTRACTIntroduction: Non-alcoholic fatty liver disease (NAFLD) represents a spectrum, including ‘simple’ steatosis, non-alcoholic steatohepatitis (NASH), and fibrosis. Increasing prevalence of NAFLD has followed the international rise in obesity and lifestyle modification is the mainstay therapy for children. To date, pharmacological trials have had varying efficacy but a large number of new agents are in early phase trials for adults.Areas covered: This review explores the effect of current and potential future paediatric NAFLD treatments in terms of histological and biochemical endpoints. The potential for the extension of adult treatments to children is discussed, as well as what limits the use of certain agents in children.Expert commentary: No drugs have yet to be licenced for NAFLD. Trial heterogeneity makes comparison of drugs between studies challenging. FXR agonists are yet to be trialled in children but may represent a safe and potentially efficacious therapy. Future treatments would likely encompass a multimodal approach that may include bariatric surgery.
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: green
OpenAlex ID: W2746158564
FWCI: 0.439
Cites: 153
Cited by: 32
Related to: 10